Sanger researcher awarded the ISTT Prize
In awarding this prize to Allan, the ISTT Prize committee acknowledges his many fundamental contributions to the science and technology of manipulating the mouse genome, throughout his career. Allan’s strong vision and leadership skills – from the Sanger Institute, in creating the EUCOMM/KOMP (IKMC) initiative, for systematic functional mouse genomics – have had a massive impact on the field of transgenic technologies.
Allan’s contributions to the field of transgenic technologies began in the1980’s with his pioneering work on embryonic stem cells, demonstrating germline transmission in 1984, revealing the potential for embryonic stem cells to generate mice carrying mutations in genes.
Allan’s team at the Sanger Institute now works on large-scale disruption of genes in embryonic stem cells and tissues of mice to discover genes involved in basic cellular processes as well as diseases like cancer. He is also the founder and Chief Scientific Officer of Kymab, a biopharmaceutical company that uses mouse genomic technologies developed by his team.
“I was thrilled to learn I had been selected to receive the ninth ISTT Prize. It is truly a great honour and I appreciate the recognition conferred by ISTT and its members. As the potential of stem cell research grows, the clinical and biological possibilities for stem cells are astounding. I am extremely grateful to have been a part of this epic journey – to see the progression from the early days of mouse genomics to where we are now is incredible.”
Allan Bradley Director Emeritus of the Wellcome Trust Sanger Institute, and Chief Scientific Officer at Kymab
Allan will present the keynote address at the meeting and will be given lifetime honorary membership in the ISTT and a sterling silver sculpture of a mouse embryonic cell created by the Hungarian artist Mr Bela Rozsnyay.
“Allan’s work is enormously influential in the area of mouse genomics. I am truly delighted that his continuing research has received recognition from the ISTT.”
Professor Mike Stratton Director of the Wellcome Trust Sanger Institute
The aim of the ISTT is to encourage knowledge generation, discussion, training and education, and the diffusion of the technologies and specific research used for the genetic modification of animals; in particular those aimed at generating or analysing transgenic animals in biology, biomedicine and biotechnology disciplines.
Allan will receive the award at the next Transgenic Technology meeting, which will be held in Guangzhou, China on February 25-27, 2013.
More information
Selected websites
The International Society for Transgenic Technologies
The International Society for Transgenic Technologies (ISTT) was founded in January 2006 and currently has ~600 members. The Society seeks to foster communication and technology sharing, to enhance scientific research, to advance the field of animal transgenesis, particularly as it applies to useful experimental models in biology, medicine and biotechnology, and to represent the interests of scientists, technicians, and graduate students working in the field of transgenic technologies. The ISTT sponsors a series of periodic international meetings known as the Transgenic Technology (TT) Meetings.
The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
